Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesaglitazar versus metformin or metformin + fenofibrate in type 2 diabetes with low HDL-cholesterol on statin background
2004-002550-56Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tesaglitazar in type 2 diabetes mellitus (T2DM) and dyslipidemia (3 arms), sponsored by AstraZeneca. Primary endpoint: Change in HDL-cholesterol from baseline to end of 24-week randomized treatment. Started Jan 2005; status: completed.
02
Drugs
tesaglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)dyslipidemia
Beyond the preview
Go deeper on 2004-002550-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002550-56.